The Alpha Glucosidase pipeline drugs market research report outlays comprehensive information on the Alpha Glucosidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Alpha Glucosidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Metabolic Disorders, Infectious Disease, and Central Nervous System which include the indications Pompe Disease, Coronavirus Disease 2019 (COVID-19), and Lafora Disease (Unverricht Disease). It also reviews key players involved in Alpha Glucosidase targeted therapeutics development with respective active and dormant or discontinued products.
The Alpha Glucosidase pipeline targets constitutes close to 27 molecules. Out of which, approximately 24 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 2, 4, 14, and 4 respectively. Similarly, the universities portfolio in Phase I, and Preclinical comprises 1, and 2 molecule.
Alpha Glucosidase overview
Alpha glucosidase are enzymes in the digestive tract that hydrolyze carbohydrates into glucose. Inhibition of enzymes involved in the digestion of carbohydrates is able to significantly decrease the postprandial increase of the glucose level in the blood, which assists with diabetes control.
For a complete picture of Alpha Glucosidase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.